Evidence map›Paper›PMID 26029828›Full record

ArticleOncogenesis2015

Regulation of lipid synthesis by the RNA helicase Mov10 controls Wnt5a production.

W Wang, N Snyder, A J Worth, I A Blair, E S Witze

Open access · goldAbstract read
In one paragraph

Article in Oncogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Unwinding the roles of RNA helicase MOV10.Wiley interdisciplinary reviews. RNA · 2022
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

W Wang1] Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA, USA [2] Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA [3] Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, USA.
N Snyder1] Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, USA [2] Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA [3] Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA [4] AJ Drexel Autism Institute, Drexel University, Philadelphia, PA, USA.
A J Worth1] Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, USA [2] Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA [3] Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
I A Blair1] Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, USA [2] Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA [3] Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
E S Witze1] Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA, USA [2] Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA [3] Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, USA.
University of Pennsylvania · USUPMC Hillman Cancer Center · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Rebecca A Simmons · 2006 to 2026
$35.3M
PREDOCTORAL TRAINING PROGRAM IN PHARMACOLOGYT32GM008076 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI BLENDY, JULIE A · 1985 to 2023
$10.8M
Translational Research Training Program in Environmental Health SciencesT32ES019851 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Kara A Bernstein, Trevor M Penning · 2012 to 2026
$6.0M
Understanding Wnt5a regulation of protein depalmitoylation during cell migrationR01CA181633 · NCI · UNIVERSITY OF PENNSYLVANIA · PI WITZE, ERIC S. · 2014 to 2018
$1.9M
NCI NIH HHS R01 CA181633NIEHS NIH HHS P30 ES013508NIEHS NIH HHS T32 ES019851NIGMS NIH HHS T32 GM008076
6 · The paper itself

Abstract

Expression of the Wnt ligand Wnt5a is frequently elevated in melanoma and is thought to be a critical regulator of cell movement during metastasis. However, the mechanisms regulating its expression are unknown. We find that the level of secreted Wnt5a varies by as much as 10-fold between cell lines and correlates more strongly with invasion than total cellular levels. Our results indicate that the RNA helicase Mov10 plays a role in Wnt5a synthesis and secretion. Inhibition of Mov10 increases secreted Wnt5a levels in melanoma cells by increasing Wnt5a synthesis and acylation. This is achieved by increasing fatty acid synthase (FASN) and stearoyl-CoA desaturase expression, leading to elevated levels of palmitoleoyl-CoA, required for Wnt ligand lipid modification and secretion. Melanoma tumors exhibit reduced expression of Mov10 compared with benign nevi and Mov10 levels inversely correlate with FASN levels in primary tumors. These results reveal a previously unappreciated role for aberrant lipid metabolism in regulating Wnt5a signaling that may be a critical step in melanoma progression.

Identifiers

PMID26029828
PMCPMC4753523
OpenAlexW915223891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.